References
- Fisher B, Costantino J., Redmond P. CK., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–537
- Barakat R R. The effect of tamoxifen on the endometrium. Oncology 1995; 9: 129–139
- Barakat R., Wong R. G., Curtin J P, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994; 55: 164–168
- Gibson L E, Barakat R R, Venkatraman E. S., et al. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J Sci Am 1995; 2: 35–38
- Lahti Blanco E. G., Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660–664
- Kedar R P, Bourne T H, Powles T. J., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318–1321
- Goldstein S R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstel Gynecol 1994; 170: 447–451